Zhang Qin-Yao, Liu Hui-Xin
Health Sciences Institute, China Medical University, Shenyang, China; Institute of Life Sciences, China Medical University, Shenyang, China; Liaoning Key Laboratory of Obesity and Glucose/Lipid Associated Metabolic Diseases, China Medical University, Shenyang, China; Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, China.
Health Sciences Institute, China Medical University, Shenyang, China; Institute of Life Sciences, China Medical University, Shenyang, China; Liaoning Key Laboratory of Obesity and Glucose/Lipid Associated Metabolic Diseases, China Medical University, Shenyang, China.
Int J Biol Macromol. 2024 Dec;282(Pt 5):136911. doi: 10.1016/j.ijbiomac.2024.136911. Epub 2024 Oct 28.
Coronary heart disease (CHD) remains a leading cause of global mortality, with an alarming increase in its incidence among the younger population in recent years. This has amplified the need for early diagnostic markers and advances in therapeutic strategies to improve patient outcomes. Fibroblast growth factor 21 (FGF21), an endocrine hormone crucial for the regulation of metabolic homeostasis, has garnered significant attention over the past decade, owing to its role in cardiovascular health. FGF21 exerts cardioprotective effects through various mechanisms, including regulation of myocardial energy metabolism, prevention of cardiac cell death, suppression of inflammation, and reduction of oxidative stress in the heart. Given these properties, FGF21 shows considerable promise as a pharmacological agent for the management of CHD. Moreover, it has emerged as a promising biomarker for the diagnosis and prognostic assessment of CHD. This review aims to clarify the molecular mechanisms underlying the favorable effects of FGF21 on CHD and its related risk factors, thereby providing valuable insights for future research on the role of FGF21 in CHD management.
冠心病（CHD）仍然是全球死亡的主要原因，近年来其在年轻人群中的发病率呈惊人的上升趋势。这加大了对早期诊断标志物的需求，并推动了治疗策略的进步以改善患者预后。成纤维细胞生长因子21（FGF21）是一种对代谢稳态调节至关重要的内分泌激素，在过去十年中因其在心血管健康中的作用而备受关注。FGF21通过多种机制发挥心脏保护作用，包括调节心肌能量代谢、预防心脏细胞死亡、抑制炎症以及减轻心脏氧化应激。鉴于这些特性，FGF21作为治疗冠心病的药物具有相当大的前景。此外，它已成为冠心病诊断和预后评估的有前景的生物标志物。本综述旨在阐明FGF21对冠心病及其相关危险因素产生有利影响的分子机制，从而为未来关于FGF21在冠心病管理中作用的研究提供有价值的见解。
